Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Cash & Equivalents (2016 - 2025)

Mimedx's Cash & Equivalents history spans 15 years, with the latest figure at $166.1 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 59.1% year-over-year to $166.1 million; the TTM value through Dec 2025 reached $166.1 million, up 59.1%, while the annual FY2025 figure was $166.1 million, 59.1% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $166.1 million at Mimedx, up from $142.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $166.1 million in Q4 2025 and bottomed at $48.5 million in Q1 2024.
  • The 5-year median for Cash & Equivalents is $84.7 million (2021), against an average of $89.0 million.
  • The largest annual shift saw Cash & Equivalents fell 24.27% in 2022 before it skyrocketed 119.5% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $87.1 million in 2021, then fell by 24.27% to $66.0 million in 2022, then rose by 24.34% to $82.0 million in 2023, then grew by 27.34% to $104.4 million in 2024, then surged by 59.1% to $166.1 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Cash & Equivalents are $166.1 million (Q4 2025), $142.1 million (Q3 2025), and $118.9 million (Q2 2025).